Abstract Number: 1835 • ACR Convergence 2021
Secukinumab Effects on Cardiometabolic Risk and Systemic Inflammation in Patients with Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis: Results from Post Hoc Analyses of Pooled Data from 19 Phase 3/4 Clinical Studies
Background/Purpose: Psoriasis (PsO), Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (AxSpA) are chronic immune-mediated inflammatory diseases (IMIDs) requiring long-term treatment. Systemic inflammation in these IMIDs is…Abstract Number: 0057 • ACR Convergence 2021
Molecular Profiling of Radiographic Axial Spondyloarthritis Patients Reveals an Association Between Innate and Adaptive Cell Populations and Therapeutic Response to Adalimumab
Background/Purpose: The response to treatment in spondylarthropaties is heterogeneous, due to factors yet to be better described. For that reason, it is important to find…Abstract Number: 0367 • ACR Convergence 2021
Can Belonging to an AxSpA Patient Organization Be Associated with Benefits to Its Members? Results from the European Map of Axial Spondyloarthritis (EMAS)
Background/Purpose: Patient organizations (POs) provide education and support services aimed to improve the quality of life of axSpA patients. This analysis aims to identify factors…Abstract Number: 0575 • ACR Convergence 2021
World Mortality of Spondyloarthritis and Inflammatory Bowel Diseases in 2015 and Its Evolution Between 2001 and 2015
Background/Purpose: There is little epidemiological data on mortality in spondyloarthritis (SpA). This study aimed to determine countries’ mortality rates of ankylosing spondylitis (AS) and psoriatic…Abstract Number: 0910 • ACR Convergence 2021
The Association of TNF Inhibitor Use with Incident Hypertension in Ankylosing Spondylitis: Data from the PSOAS Cohort
Background/Purpose: Ankylosing spondylitis (AS) is associated with greater cardiovascular (CV) risk than in the general population. The impact of tumor necrosis factor inhibitors (TNFi) on…Abstract Number: 1045 • ACR Convergence 2021
Composition of Phospholipid Fatty Acids in Erythrocyte Membranes from Patients with Ankylosing Spondylitis
Background/Purpose: To investigate the composition of phospholipid fatty acids in erythrocyte membranes from patients with ankylosing spondylitis (AS), and determine the correlations between the percentage…Abstract Number: 1919 • ACR Convergence 2021
Detection of Radiographic Sacroiliitis with an Artificial Neural Network in Patients with Suspicion of Axial Spondyloarthritis
Background/Purpose: Conventional radiography of the sacroiliac joints is still recommended as the first imaging method for the diagnosis of axial spondyloarthritis (axial SpA). In many…Abstract Number: 0063 • ACR Convergence 2021
Development of a Novel Cartilage Model Co-cultured with Conditioned Medium from Th17 Cells to Explore the Effect of IL-17A on Joint Tissue Remodeling
Background/Purpose: In spondyloarthritis (SpA) Th17 cells play a critical role in activating the pathogenic chain leading to manifestations related to skin, joints and entheses. Elevated…Abstract Number: 0368 • ACR Convergence 2021
Geographical Prevalence of Family History in Patients with Axial SpA and Its Association with HLA-B27: Data from the Worldwide ASAS-perSpA Study
Background/Purpose: Research has shown that in patients with axial spondyloarthritis (axSpA), the most common form of spondyloarthritis (SpA) in a family history is axSpA. Moreover,…Abstract Number: 0748 • ACR Convergence 2021
Performance of Standardized Scores for Disease Assessment and Pain in Patients Withspondyloarthritis and Fibromyalgia
Background/Purpose: The pathogenesis of spondyloarthritis (SpA) including axial SpA (axSpA) and psoriatic arthritis (PsA) differs from fibromyalgia (FM). However, symptoms partially overlap and both patient…Abstract Number: 0911 • ACR Convergence 2021
Drug Retention of Tumor Necrosis Factors and IL-17 Inhibitors in Axial Spondyloarthritis: A Multi-Center Comparative Analysis
Background/Purpose: Biological disease-modifying antirheumatic drugs (bDMARDs) should be considered in patients with active axial spondyloarthritis (AxSpA) despite treatment with nonsteroidal anti-inflammatory drugs. The objective of…Abstract Number: 1093 • ACR Convergence 2021
Cardiovascular and Lipid Biomarker Distributions in Inflammatory Arthritis
Background/Purpose: Inflammatory arthritis (IA) is associated with cardiovascular disease (CVD). Cardiac biomarkers may assist with CVD risk stratification. We aimed to estimate the prevalence, and…Abstract Number: 1922 • ACR Convergence 2021
Early and Accurate Diagnosis of Patient with Axial Spondyloarthritis Using Machine Learning: A Predictive Analysis from Electronic Health Records in United Kingdom
Background/Purpose: On an average, there is a delay of 6.7 years between symptom onset and diagnosis of axial spondyloarthritis (axSpA)1. Since traditional approaches to improving…Abstract Number: 0065 • ACR Convergence 2021
Altered Expression of Several miRNAs in Axial Spondyloarthritis Patients with High Disease Activity
Background/Purpose: Recent studies have shown that microRNAs (miRNAs) play a role in various disorders, including immune mediated inflammatory diseases. Therefore, we studied relationship between miRNA…Abstract Number: 0369 • ACR Convergence 2021
High Frequency of Complications in Axial Spondyloarthropathy Pregnancies: Emerging Data from the Ankylosing Spondylitis Registry of Ireland
Background/Purpose: National registries are excellent sources of data to allow analysis of inflammatory arthritis such as axial spondyloarthropathy (axSpA). Our understanding of axSpA has evolved…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 62
- Next Page »